<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=us-ascii">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Georgia;
panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
{font-family:"
panose-1:0 0 0 0 0 0 0 0 0 0;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
h1
{mso-style-priority:9;
mso-style-link:"Heading 1 Char";
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:24.0pt;
font-family:"Calibri",sans-serif;
font-weight:bold;}
h2
{mso-style-priority:9;
mso-style-link:"Heading 2 Char";
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:18.0pt;
font-family:"Calibri",sans-serif;
font-weight:bold;}
h3
{mso-style-priority:9;
mso-style-link:"Heading 3 Char";
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:13.5pt;
font-family:"Calibri",sans-serif;
font-weight:bold;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
span.EmailStyle17
{mso-style-type:personal-compose;
font-family:"Calibri",sans-serif;
color:windowtext;}
span.Heading1Char
{mso-style-name:"Heading 1 Char";
mso-style-priority:9;
mso-style-link:"Heading 1";
font-family:"Calibri",sans-serif;
font-weight:bold;}
span.Heading2Char
{mso-style-name:"Heading 2 Char";
mso-style-priority:9;
mso-style-link:"Heading 2";
font-family:"Calibri",sans-serif;
font-weight:bold;}
span.Heading3Char
{mso-style-name:"Heading 3 Char";
mso-style-priority:9;
mso-style-link:"Heading 3";
font-family:"Calibri",sans-serif;
font-weight:bold;}
p.byline-dateline, li.byline-dateline, div.byline-dateline
{mso-style-name:byline-dateline;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.byline
{mso-style-name:byline;}
span.byline-author
{mso-style-name:byline-author;}
span.sharetools-label
{mso-style-name:sharetools-label;}
span.sharetool-text
{mso-style-name:sharetool-text;}
span.visually-hidden
{mso-style-name:visually-hidden;}
span.caption-text
{mso-style-name:caption-text;}
span.credit
{mso-style-name:credit;}
p.story-body-text, li.story-body-text, div.story-body-text
{mso-style-name:story-body-text;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.title
{mso-style-name:title;}
p.summary, li.summary, div.summary
{mso-style-name:summary;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.z-TopofFormChar
{mso-style-name:"z-Top of Form Char";
mso-style-priority:99;
mso-style-link:"z-Top of Form";
font-family:"Arial",sans-serif;
display:none;}
span.z-BottomofFormChar
{mso-style-name:"z-Bottom of Form Char";
mso-style-priority:99;
mso-style-link:"z-Bottom of Form";
font-family:"Arial",sans-serif;
display:none;}
.MsoChpDefault
{mso-style-type:export-only;
font-family:"Calibri",sans-serif;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:311371561;
mso-list-template-ids:-145184974;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1
{mso-list-id:557087298;
mso-list-template-ids:-304998074;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2
{mso-list-id:1557274268;
mso-list-template-ids:572021250;}
@list l2:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l2:level3
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level4
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level5
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level6
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level7
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level8
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level9
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<h1 style="mso-margin-top-alt:0in;margin-right:0in;margin-bottom:7.5pt;margin-left:0in;line-height:28.45pt">
<i><span style="font-size:25.5pt;font-family:""",serif;color:black"><a href="https://www.nytimes.com/2018/02/25/science/fda-medication-assisted-therapy.html">F.D.A. to Expand Medication-Assisted Therapy for Opioid Addicts</a><o:p></o:p></span></i></h1>
<p class="byline-dateline" style="mso-margin-top-alt:0in;margin-right:33.75pt;margin-bottom:2.25pt;margin-left:0in;line-height:12.75pt;times new roman"times,serif">
<span class="byline"><b><span style="font-size:8.0pt;font-family:""",serif">By
<a href="https://www.nytimes.com/by/sheila-kaplan" title="More Articles by SHEILA KAPLAN">
<span class="byline-author"><span style="color:black;text-decoration:none">SHEILA KAPLAN</span></span></a><o:p></o:p></span></b></span></p>
<p class="byline-dateline" style="mso-margin-top-alt:0in;margin-right:33.75pt;margin-bottom:2.25pt;margin-left:0in;line-height:12.75pt">
<span style="font-size:12.0pt;font-family:"Georgia",serif">FEB. 25, 2018 <o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:""",serif;color:#333333"><img border="0" width="768" height="566" style="width:8.0in;height:5.8958in" id="Picture_x0020_5" src="cid:image001.jpg@01D3AFA2.78DDC940" alt="https://static01.nyt.com/images/2018/02/25/business/26OPIOD/26OPIOD-master768.jpg"></span><span style="font-size:12.0pt;font-family:""",serif;color:#333333"><o:p></o:p></span></p>
<p class="MsoNormal"><span class="caption-text"><span style="font-size:9.5pt;font-family:""",serif;color:#666666">Alex M. Azar II, the secretary of health and human services, speaking to the National Governors Association on Saturday in Washington. The
Trump administration wants to expand access to so-called medication-assisted treatment for combating opioid addiction.</span></span><span style="font-size:12.0pt;font-family:""",serif;color:#333333">
</span><span class="visually-hidden"><span style="font-size:8.0pt;font-family:""",serif;color:#999999;border:none windowtext 1.0pt;padding:0in">Credit</span></span><span class="credit"><span style="font-size:8.0pt;font-family:""",serif;color:#999999">
Jose Luis Magana/Associated Press </span></span><span style="font-size:12.0pt;font-family:""",serif;color:#333333"><o:p></o:p></span></p>
<p class="story-body-text" style="mso-margin-top-alt:0in;margin-right:0in;margin-bottom:12.7pt;margin-left:56.25pt;line-height:19.45pt">
<span style="font-size:12.5pt;font-family:"Georgia",serif;color:#333333">In an effort to encourage new treatments for opioid addiction, the Food and Drug Administration plans to begin permitting pharmaceutical companies to sell medications that help temper
cravings, even if they don’t fully stop addiction.<o:p></o:p></span></p>
<p class="story-body-text" style="mso-margin-top-alt:0in;margin-right:0in;margin-bottom:0in;margin-left:56.25pt;margin-bottom:.0001pt;line-height:19.45pt;times new roman"times,serif;max-width:none">
<span style="font-size:12.5pt;font-family:"Georgia",serif;color:#333333">The change is part of a wider effort to expand access to so-called medication-assisted treatment, or MAT. The agency will issue draft guidelines in the next few weeks. A senior agency
official provided details of the proposal to The New York Times<em><span style="font-family:"Georgia",serif">.</span></em><o:p></o:p></span></p>
<p class="story-body-text" style="mso-margin-top-alt:0in;margin-right:0in;margin-bottom:12.7pt;margin-left:56.25pt;line-height:19.45pt;times new roman"times,serif;max-width:none">
<span style="font-size:12.5pt;font-family:"Georgia",serif;color:#333333"><br>
The new approach was signaled Saturday by the health and human services secretary, Alex M. Azar II, in remarks to the National Governors Association. Mr. Azar said the agency intended “to correct a misconception that patients must achieve total abstinence in
order for MAT to be considered effective.”<o:p></o:p></span></p>
<p class="story-body-text" style="mso-margin-top-alt:0in;margin-right:0in;margin-bottom:12.7pt;margin-left:56.25pt;line-height:19.45pt;times new roman"times,serif;max-width:none">
<span style="font-size:12.5pt;font-family:"Georgia",serif;color:#333333">While the Trump administration has generally supported medication-assisted treatment, Mr. Azar’s predecessor, Tom Price, was not completely on board with it. Mr. Price caused an uproar
among treatment experts when he dismissed some medications that reduce cravings through synthetic opioids last spring as substituting one opioid for another. He subsequently walked back those comments, saying officials should be open to a broad range of treatment
options.<o:p></o:p></span></p>
<p class="story-body-text" style="mso-margin-top-alt:0in;margin-right:0in;margin-bottom:12.7pt;margin-left:56.25pt;line-height:19.45pt;times new roman"times,serif;max-width:none" id="story-continues-1">
<span style="font-size:12.5pt;font-family:"Georgia",serif;color:#333333">Mr. Azar,
<a href="https://www.nytimes.com/2018/01/24/us/politics/alex-azar-health-and-human-services-secretary-confirmed-senate.html">
<span style="color:#326891">who took office late last month</span></a>, said he would work to reduce the stigma associated with addiction and addiction therapy, and would not treat it as a moral failing.<o:p></o:p></span></p>
<p class="story-body-text" style="mso-margin-top-alt:0in;margin-right:0in;margin-bottom:12.7pt;margin-left:56.25pt;line-height:19.45pt">
<span style="font-size:12.5pt;font-family:"Georgia",serif;color:#333333">The opioid epidemic is considered the most unrelenting drug crisis in United States history. In 2016, roughly 64,000 people were killed by opioid-related overdoses, including from prescription
painkillers and heroin.<o:p></o:p></span></p>
<p class="story-body-text" style="mso-margin-top-alt:0in;margin-right:0in;margin-bottom:12.7pt;margin-left:56.25pt;line-height:19.45pt;times new roman"times,serif;max-width:none">
<span style="font-size:12.5pt;font-family:"Georgia",serif;color:#333333">Noting federal data showing that only one-third of specialty substance abuse treatment programs offer medication-assisted treatment, Mr. Azar said, “We want to raise that number — in fact,
it will be nigh impossible to turn the tide on this epidemic without doing so.”<o:p></o:p></span></p>
<p class="story-body-text" style="mso-margin-top-alt:0in;margin-right:0in;margin-bottom:12.7pt;margin-left:56.25pt;line-height:19.45pt">
<span style="font-size:12.5pt;font-family:"Georgia",serif;color:#333333">Mr. Azar’s comments echo those of the F.D.A. chief, Dr. Scott Gottlieb, who has made battling opioid abuse a priority for his agency. Dr. Gottlieb has moved to reduce opioid prescriptions
by doctors and dentists and to promote more medication-assisted treatment, defined as drugs used to stabilize brain chemistry, reduce or block the euphoric effects of opioids, relieve physiological cravings, and normalize body functions.<o:p></o:p></span></p>
<p class="story-body-text" style="mso-margin-top-alt:0in;margin-right:0in;margin-bottom:12.7pt;margin-left:56.25pt;line-height:19.45pt;times new roman"times,serif;max-width:none">
<span style="font-size:12.5pt;font-family:"Georgia",serif;color:#333333">The F.D.A. has approved three drugs for opioid treatment — buprenorphine (often known by the brand name Suboxone), methadone and naltrexone (known by the brand name Vivitrol) — and says
they are safe and effective combined with counseling and other support. But the agency said it would soon publish two guidances, recommendations for drugmakers, on the issue.<o:p></o:p></span></p>
<p class="story-body-text" style="mso-margin-top-alt:0in;margin-right:0in;margin-bottom:0in;margin-left:56.25pt;margin-bottom:.0001pt;line-height:19.45pt;times new roman"times,serif;max-width:none">
<span style="font-size:12.5pt;font-family:"Georgia",serif;color:#333333">One encourages the development of new, longer-acting formulations of existing drugs for opioid treatment. The other, which was described in detail to The Times<em><span style="font-family:"Georgia",serif">,
</span></em>said new drugs would be eligible for approval that don’t end addiction but help with aspects of it, such as cravings, or overdoses, with the goal remaining complete abstinence.<o:p></o:p></span></p>
<p class="story-body-text" style="mso-margin-top-alt:0in;margin-right:0in;margin-bottom:12.7pt;margin-left:56.25pt;line-height:19.45pt;times new roman"times,serif;max-width:none">
<span style="font-size:12.5pt;font-family:"Georgia",serif;color:#333333"><br>
“We will permit an endpoint that shows substantial reductions but does not require the patient to be totally clean at every visit if the measurements are fairly frequent,” a senior F.D.A. official said.<o:p></o:p></span></p>
<p class="story-body-text" style="mso-margin-top-alt:0in;margin-right:0in;margin-bottom:12.7pt;margin-left:56.25pt;line-height:19.45pt;times new roman"times,serif;max-width:none">
<span style="font-size:12.5pt;font-family:"Georgia",serif;color:#333333">The official also said the F.D.A. was seeking medications that can help patients function better and can be helpful when used in combination with therapy and other social support, even
if on their own the medications don’t completely end addiction. Under the new guidelines, patients and their families will have input in assessing how useful a drug is.<o:p></o:p></span></p>
<p class="story-body-text" style="mso-margin-top-alt:0in;margin-right:0in;margin-bottom:12.7pt;margin-left:56.25pt;line-height:19.45pt;times new roman"times,serif;max-width:none" id="story-continues-4">
<span style="font-size:12.5pt;font-family:"Georgia",serif;color:#333333">“You could envision different MATs where the different treatments are addressing different aspects of what underlies the addiction, and helping people lead productive lives free from addiction
to opioids, even in situations where they still might require replacement therapy,” the official said.<o:p></o:p></span></p>
<p class="story-body-text" style="mso-margin-top-alt:0in;margin-right:0in;margin-bottom:12.7pt;margin-left:56.25pt;line-height:19.45pt;times new roman"times,serif;max-width:none">
<span style="font-size:12.5pt;font-family:"Georgia",serif;color:#333333">Addiction experts were cautious in their praise of the plan, which should be released in March.<o:p></o:p></span></p>
<p class="story-body-text" style="mso-margin-top-alt:0in;margin-right:0in;margin-bottom:12.7pt;margin-left:56.25pt;line-height:19.45pt;times new roman"times,serif;max-width:none">
<span style="font-size:12.5pt;font-family:"Georgia",serif;color:#333333">“The F.D.A. should keep companies focused on major clinical improvement for patients,” said Yngvild Olsen,medical director of the Institutes for Behavior Resources in Baltimore. “A more
thoughtful approach to measuring meaningful clinical improvement could expand treatment options, but there is a danger; subjective outcomes that are neither here nor there could encourage the development of products of questionable value.”<o:p></o:p></span></p>
<p class="story-body-text" style="mso-margin-top-alt:0in;margin-right:0in;margin-bottom:12.7pt;margin-left:56.25pt;line-height:19.45pt;times new roman"times,serif;max-width:none">
<span style="font-size:12.5pt;font-family:"Georgia",serif;color:#333333">And Dr. Andrew Kolodny, a director of opioid policy research at Brandeis University, said that the F.D.A. was smart to look for new treatments but that the biggest problem now in treatment
wasn’t lack of effective medication, but lack of access.<o:p></o:p></span></p>
<p class="story-body-text" style="mso-margin-top-alt:0in;margin-right:0in;margin-bottom:12.7pt;margin-left:56.25pt;line-height:19.45pt;times new roman"times,serif;max-width:none">
<span style="font-size:12.5pt;font-family:"Georgia",serif;color:#333333">“We already have an effective treatment that people aren’t getting access to,” he said. “The primary challenge is getting it to people.”<o:p></o:p></span></p>
<p class="MsoNormal"><o:p> </o:p></p>
</div>
</body>
</html>